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ABSTRACT 
 
Cow’s milk allergy (CMA) is the most frequent food allergy in children and oral 
immunotherapy (OIT) is a promising approach for treatment of patients. The most challenging 
cases are anaphylactic with coexisting asthma and proposing safe protocols is crucial especially in 
high risk groups. Considering that CMA varies among patients, an individualized OIT protocol 
would be beneficial to achieve a safer and more efficient method of desensitization. 
18 children more than 3 years of age with IgE-mediated CMA were enrolled. CMA was 
confirmed by positive skin prick test (SPT) and positive oral food challenge (OFC) and 60% of 
individuals had a convincing history of persistent asthma. SPT with milk extracts, whole fresh 
milk and serially diluted milk concentrations were performed.  The dilution of milk that induced 
3-5 mm of wheal in each individual was selected as the starting dilution for OIT. Desensitization 
began by 1 drop of the defined dilution and continued increasingly.  
Overall, 16 out of 18 children (88.8%) achieved the daily intake of 120 mL of milk. Four out 
of these 16 children accomplished the protocol without any adverse allergic reactions. 12 patients 
experienced mild to severe reactions. Wheal and erythema in SPT (p≤0.001), and sIgE (p≤0.003) 
to most milk allergens were significantly decreased following desensitization. 
We successfully desensitized 16 of 18 children with IgE-mediated CMA by individualized 
desensitization protocol. Individualizing the OIT protocol would be helpful to save time and 
perhaps to relieve the allergic symptoms after ingesting cow’s milk intake. 
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INTRODUCTION 
 
Milk allergy is the most common food allergy in 
children (both IgE- and non-IgE-mediated 
hypersensitivities). It can be severe particularly in those 
having a positive  history of anaphylaxis to milk and a 
higher level of specific immunoglobulin E (sIgE).
1
 
Most infants with non-IgE-mediated cow’s milk allergy 
(CMA) outgrow their sensitivity by the age of three,
2,3
 
While 10% to 25% of infants with IgE-mediated CMAs 
keep their sensitivity into second decade. Some studies 
have shown that only 19% of milk allergies are 
alleviated by the age of 4 and about 80% by the age of 
16 years.
4,5
 
The basic treatment for the milk allergy has been an 
elimination diet and waiting for natural tolerance.  This 
treatment is effective in some cases; however, 
elimination diet for a long period of time may result in 
malnutrition, eating disorders, and other psychological 
problems.
6-9 
Therefore dietary or pharmaceutical 
supplementation is advised for these patients.
10
 Aside 
from avoidance, active disease-modifying therapy for 
food allergy has been studied in recent years and 
several reports have emerged on milk oral 
immunotherapy (OIT), or using heated products of milk 
or egg, in patients with severe reactions to cow’s milk 
(CM) protein.
5,11-13
 However, data on the efficacy, 
safety, course and long-term outcome, especially in 
asthmatic patients are limited.
14
 
Since the introduction of oral tolerance,
15 
the exact 
immunological mechanism of OIT is not fully 
understood,
16,17
 but it has been more studied recently 
due to severe systemic reactions following traditional 
type of immunotherapy.
5.18,19
 OIT is becoming an 
increasingly common treatment for food allergies. It 
usually contains two phases: build up and maintenance. 
The former could be slow (conventional) or fast (rush) 
until the target dose is achieved. The latter involves 
daily consumption of the final dose.
5,6,20
  
There are so many factors affecting the efficacy of 
OIT such as the schedule of immunotherapy, severity 
of anaphylaxis, presence of other risk factors like 
asthma, age of desensitization. On the other hand the 
factors affecting the efficacy of OIT are complicated 
and dependent on patients’ immune system. Most of 
protocols have a same manner for all patients, without 
any personal modification in doses. Therefore, we 
designed this trial to recruit patients with CM 
anaphylaxis to achieve a personalized, safe and 
efficient oral desensitization protocol, especially in 
patients with concurrent asthma. 
 
PATIENTS AND METHODS 
 
Patients over than 3 years of age, with a convincing 
history of anaphylaxis to CM and positive skin prick 
test (SPT) confirmed by positive oral food challenge 
(OFC) were admitted to the OIT trial. Trial started 2 
months after the last anaphylaxis to milk. Patients with 
underlying cardiopulmonary disorders, uncontrolled 
asthma, any significant systemic disease, and poor 
compliance were excluded from the study. Among 25 
children, 18 were recruited in Rasool-e-Akram 
Hospital, Tehran, Iran University of Medical Sciences 
and Mofid Children’s Hospital, Tehran, Shahid 
Beheshti University of Medical Sciences from June 
2013 to the end of 2014. Five children were excluded 
because of unstable asthma and two due to uncontrolled 
seizures. 18 patients were recruited 
A detailed clinical history including: sex, age, 
family and personal history of allergies, symptoms after 
previous ingestion of CM was taken and a written 
informed consent was collected. SPT with some 
commercial common inhalant allergens including, mite 
mixture, alternaria, tree mix, grass mix, weed mix, and 
food allergens including peanut, walnut, hazelnut, egg, 
wheat, soy and fish mix (Greer, USA) was done. 
Histamine (1:1.000) and glycerine were used as 
positive and negative controls, respectively. Prick to 
prick was also performed by applying 1 drop of fresh 
milk and 1:10, 1:25, 1:50, 1:100, 1:200, 1:400, and 
1:500 milk dilutions. In addition to SPT, CM, α 
lactoalbumin, β lactoglobulin, casein, and bovine serum 
albumin specific IgEs were measured using an 
immunoblotting method (R-biopharm, Darmstadt, 
Germany).  
 
Milk Desensitization Protocol 
SPT with the milk extract and dilutions of fresh 
milk were done for all recruited patients. The dilution 
of milk that induced 3-5 mm of wheal was selected  
as the starting dilution for each individual and we 
started with one drop of the determined dilution. In the 
first session the CM doses were doubled every 15 
minutes up to 16 drops, and then it was continued 
through the next week. In the second week, the 
previous dose was increased two-folded and continued 
through the week. The dilution of milk was changed 
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biweekly according to the protocol (Table 1), in order 
to achieve a total daily intake of 120 mL. If any 
symptoms such as common cold, viral diarrhea, fever, 
etc. were observed during the oral desensitization, the 
dose was not increased and the previous dose was 
repeated. No ingestion of CM was allowed out of  
the scheduled protocol. All the new doses were 
administered under medical supervision in a clinical 
setting. 30 minutes after receiving each dose, patients 
were carefully assessed for positive reactions. Mild 
reactions were managed by antihistamines and severe 
reactions and anaphylaxis were managed by 
epinephrine, steroid, and antihistamine. Patients who 
developed moderate to severe reactions were observed 
at least 4 h in emergency department or admitted if 
needed. In case of anaphylaxis, the applying dose 
returned to the previous tolerated dose for one week 
and then it was increased by half of the last one. This 
protocol was approved by medical ethics committee in 
Shahid Beheshti University of Medical Sciences and 
was registered in Iranian Registry of Clinical Trials 
(IRCT) with the following identifier: 
IRCT2013080814305N1. 
 
Blood Samples 
Venous blood samples were collected at the 
beginning of the protocol and after desensitization to 
determine sIgEs against milk and its components. Total 
serum IgE, using an immunoblotting method (R-
biopharm, Darmstadt, Germany), and absolute 
eosinophil count were measured as well. 
 
Statistical Analysis 
Statistical analyses were performed using SPSS 16 
software (IBM Corp., Armonk, N.Y., USA). Mean, 
standard deviation, and median were used for 
descriptive quantitative data, and frequency was used 
for analysis of qualitative data. Paired T-test was used 
for the comparison of wheal and flare sizes before and 
after OIT. Logistic regression was used to evaluate the 
effect of risk factors (food or aeroallergen sensitization, 
past medical history and/or family history of atopy, and 
current asthma or other allergic disorders) on the 
success of the protocol. sIgE levels before and after 
OIT was compared by non-parametric Wilcoxon signed 
rank test. A p value ≤0.05 was considered significant 
for all comparisons. 
 
RESULTS 
 
18 patients were recruited to the study, 11 males 
(61%), and 7 females (38.9%), ranged from 3 to 19 
years (Mean=6.9). 11 of the 18 children (≈68%) 
suffered from asthma, 8 (≈44%) from allergic rhinitis, 
and 3(≈11%) from urticaria. All of the patients had a 
positive history of allergic diseases in their infancy. 
SPT revealed sensitization against aeroallergens 
(including mite, alternaria, tree mix, grass mix, and 
weed mix) in 7 patients (41.2%), eggs in 8 patients 
(41.7%), and nuts in 5 patients (29%). Mean total IgE 
of patients was 177 KIU/L (ranged from 26 to 400) and 
mean of absolute eosinophil count was 414 cell/L 
(ranged from 0-1250). 
 
Table 1. Time table of oral immunotherapy using cow's milk 
Week of visit 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 
Dilution of milk 1:500* 1:400* 1:200* 1:100* 1:50* 1:25* 1:10* Full dilution of milk 
Drops ingested 2 16 5 10 5 10 5 10 5 10 5 10 5 10 5* 2¶ 4 8 16 32 64 120 
Each 15 minute  2 16 5 10 5 10 5 10 5 10 5 10 5 10 5        
 4              10        
 8 
 
 
                     
Total dose during 
each week 
16 32 10 20 10 20 10 20 10 20 10 20 10 20 20 2 4 8 16 32 64 120 
*drops, ¶milliliter of milk 
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Table 2. Age, sex, starting dilution, symptoms during cow’s milk (CM) desensitization, treatment, and outcome of the 
desensitization protocol 
Patient ID Age Sex Starting 
Dilution 
Outcome of 
desensitization 
Symptoms during 
CM desensitization 
Dose of CM 
when 
symptoms 
intervened 
Treatment 
1 
 
 3.00 M 1:400 120cc Wheezing, Urticaria 20gtt*    1:200 Epinephrine 
+Steroid+ 
Antihistamine 
      Vomiting, Wheezing 10gtt     1:50 Epinephrine 
+Steroid+ 
Antihistamine 
      Uricaria, Cough 32cc       Full 
 
Epinephrine 
+Steroid+ 
Antihistamine 
2  11.00 M 1:400 120 cc Wheezing, Urticaria, 
Vomiting 
16 cc      Full Epinephrine 
+Steroid+ 
Antihistamine 
3  3.00 M 1:200 120 cc Vomiting, Wheezing,       
Urticaria 
20gtt   1:100 Epinephrine 
+Steroid+ 
Antihistamine 
      Uricaria, Abdominal pain 16cc     Full Epinephrine 
+Steroid+ 
Antihistamine 
4  3.00 M 1:100 120 cc    
5  4.00 M 1:400 120 cc    
6  3.00 M 1:400 120 cc 
 
Wheezing, Cough, 
urticaria 
20gtt   1:10 Epinephrine 
+Steroid+ 
Antihistamine 
7  3.00 M 1:500 120 cc Wheezing, Urticaria 10gtt    Full Epinephrine 
+Steroid+ 
Antihistamine 
      Abdominal pain, wheezing 16 cc    Full Epinephrine 
+Steroid+ 
Antihistamine 
      Urticaria 32 cc    Full Antihistamine 
      Uricaria, Cough, 
Hoarsness 
64cc     Full Epinephrine 
+Steroid+ 
Antihistamine 
8  19.00 F 1:400 120 cc Abdominal Discomfort 16cc     Full Antihistamine 
9  4.00 F 1:400 120 cc Wheezing, Sneezing, 
Agitation, Rhinorrhea 
32cc     Full Epinephrine 
+Steroid+ 
Antihistamine 
      Abdominal pain, Urticatia 64 cc    Full Epinephrine 
+Steroid+ 
Antihistamine 
10  5.00 F 1:10 120 cc    
11  4.00 F 1:200 120 cc Flushing, Urticaria, 
Cough, 
20gtt    1:50 Epinephrine 
+Steroid+ 
Antihistamine 
      Pallor, Wheezing, Cough 10gtt    1:10 Epinephrine 
+Steroid+ 
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Antihistamine 
      Cough attack, Hoarseness 64cc      Full Epinephrine 
+Steroid+ 
Antihistamine 
12  13.00 M 1:25 120 cc    
13  5.00 M 1:400 120 cc Mouth itching 8cc     Full Antihistamine 
 
14  3y F 1:400 Discontinue at 
64 cc of Full 
 
   
15  7y F 1:500 Discontinue 
At 16cc of full 
 
Mouth itching, Vomiting, 
Urticaria 
20gtt   1:200 Epinephrine 
+Steroid+ 
Antihistamine 
      Hoarseness, Urticaria, 
Wheeze 
2c c     Full Epinephrine 
+Steroid+ 
Antihistamine 
      Wheeze, Abdominal pain, 
Urticaria 
4cc      Full Epinephrine 
+Steroid+ 
Antihistamine 
      Wheeze, Cough, Urticaria 16cc    Full Epinephrine 
+Steroid+ 
Antihistamine 
      Wheeze, Oral Itching, 
Urticaria 
16cc    Full Epinephrine 
+Steroid+ 
Antihistamine 
16  13y M 1:50 120 cc Urticaria 32cc   Full Antihistamine 
17  9 F 1:200 120 cc Mouth and lip itching 16cc    Full Antihistamine 
18  12y M 1:10 120 cc  120cc  Full  
*gtt: drops 
 
 
Desensitization started from the 1:400 dilution of 
milk in 44% of patients and 1:200 in 16.7% of patients. 
The period of desensitization varied between 10 to 27 
weeks. Overall, 16 of the 18 children (88.8%) achieved 
the daily intake of 120 mL of milk (Table 2). Among 
these children, four accomplished the protocol without 
showing any symptoms, and 12 presented moderate to 
severe symptoms (Table 1). Totally, 498 doses were 
administered and 21 episodes of anaphylaxis happened 
during this trial, and the mean number of anaphylaxis 
was 1.17 (median=0.5). Nine patients achieved 120 cc 
of full milk without any anaphylaxis. We did not find 
any significant correlation between aeroallergen or 
food sensitization, PMH or family history of atopy, 
coexisting of an allergic disorders and the number of 
anaphylaxis during desensitization (data not shown, 
p>0.05). One of the patients (No.15) quitted the 
protocol because of several severe anaphylaxis and 
serious asthma exacerbations. Of note, Patient No.14 
developed recurrent abdominal pain and after 
endoscopy and biopsy was diagnosed as eosinophilic 
esophagitis (EoE). All of the other tolerant patients 
were followed 1 year after OIT and were able to 
consume more than 120 cc of milk and other dairy 
products in a day.  
The mean SD size of wheal in SPT before OIT 
(12±5.1 mm) significantly decreased to 5.83±3.34 mm 
after desensitization (p≤0.001, CI 95%; 3.2-9). Also, 
data showed significant reduction of erythema 
following SPT after desensitization (p=0.001, CI95%; 
7-20.9) (Table 3). The mean and interquartile range 
(IQR) for the levels of serum specific IgE against milk 
and its components (casein, α lactalbumine, β 
lactoglobuline, and serum bovine albumin) before and 
after desensitization is shown in Table 4. As shown, a 
significant decrease in specific IgE level against milk 
and its components, except serum bovine albumin was 
observed.
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Table 3. Outcome of the point skin prick tests (SPTs) with milk extract at the beginning, and at the end of the oral 
immunotherapy 
 Before desensitization After desensitization change p value 
Mean (mm) Mean (mm) 
Skin prick test Wheal 12±5.1* 5.83± 3.34 6.1 (3.2-9)¶ 0.000 
Skin prick test Erythema 24.61±8.51 12.27± 7.93 14 (7-20.9) 0.001 
* Mean ± Std. Deviation 
¶95% Confidence interval of the difference 
 
 
Table 4. Results of specific IgE levels against whole cow's milk, casein, α-lactoalbumin, β lactoglobuline, and serum bovine 
albumin, before and after the oral desensitization 
 Before desensitization After desensitization p-value 
 Mean (IU/mL) IQR Mean (IU/mL) IQR  
sIgE to whole milk  3.1875 1.75 2.3125 1 0.003 
sIgE to α lactoalbumin 3.1333 1 2.6000 1 0.020 
sIgE to βlactoglobuline 3.3750 1 2.3125 1.75 0.014 
sIgE to Casein  3.3125 1 2.3750 1 0.019 
sIgE to serum Bovine albumin 1.7143 3 1.7692 3.3 0.705 
 
 
DISCUSSION 
 
In this study we described a new personalized 
desensitization protocol for treatment of cow’s milk 
anaphylaxis.  We specifically chose the starting dilution 
for each patient, then gradually increased doses or 
changed the dilutions. Due to different starting doses 
the period of desensitization ranged between 10 to 27 
weeks. The overall success rate of OIT was 88.8%, 
meaning that 16 patients could intake at least 120 mL 
of milk per day. The success rate of our trial with 
respect to the severity of adverse allergic reactions in 
patients with CM anaphylaxis was considerable. 
Despite precautions taken by patients and their 
families, incidental ingestion of milk via processed 
foods may cause severe anaphylactic reaction and 
affect the quality of life.
21 
Consequently, efforts have 
been made to substitute the elimination diet with 
desensitization or tolerance induction modalitis. 
According to the BSACI Guidelines,
22
 regarding 
milk allergy, wheal size equal or more than 5 mm (≥2 
mm in younger infants) after SPT is strongly predictive 
for allergy to CM proteins. Therefore, reduced wheal 
and flare in our patients after desensitization confirm 
their clinical response and could be indicative of 
tolerance induction. As data shown here, wheal and 
erythema reactions following SPT were significantly 
decreased in patients after OIT with CM.
 
  
There are some experiences about milk OIT. 
Skripak et al., reported a randomized OIT to milk or 
placebo in 20 children, according to a 3-phase protocol. 
They started from 0.4 mg of milk protein and reached 
to 50 mg daily.
23 
Zapatero et al.,
24
 desensitized 18 
children older than 4 years with CM protein allergy, 
89% of patients achieved a tolerance with 200-250 mL 
of milk in a day. Meglio et al.,
6
 published a 
desensitization protocol that began with 1 drop of a 
1:25 dilution of milk increasing to 200 mL on day 180 
(6
th 
months). 71.4% of patients achieved the final dose, 
while some of them were partially tolerant. Bauer et 
al.
25
 reported a rapid oral desensitization in a 12-year-
old girl, using 0.01 mL of milk then increasing two-
folded until 200 mL on day 5 after desensitization. 
Staden et al.,
10
 reported a desensitization protocol for 
induction of tolerance in 9 children over 3 years of age. 
They started from 1:100 of the eliciting dose, and then 
a two-folded increased dose was administered after 2 h 
with 3 to 5 doses in a day. Doses were increased up to 
120 mL of CM. Patriarca et al.11 began their OIT 
protocol with 1 drop of milk and increased it up to 120 
mL over a period of 136 days. From 16 children 
enrolled in that study, 13 (76.9%) completed the 
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desensitization in 3-12 months, while 3 had to quit the 
trial due to severe adverse effects. 
In our study 16 of the 18 participating patients 
(89%) achieved a tolerance to 120 mL of cow’s milk a 
day, and we used personalized starting dose based on 
SPT.  Six patients under 4 years of age finished the 
protocol successfully; therefore, it seems that starting 
OIT in children over 3 years was effective and 
decreased the chance of anaphylactic reactions after 
accidental exposure to allergens. Our finding was 
similar to Meglio et al.'s and Bauer et al.'s studies, who 
demonstrated promising results after OIT therapy in 
atopic patients.
6,25
 In contrast to other studies, we 
started the desensitization based on patient’s SPT 
results, so the dose and duration of protocol varied 
among patients. Individualizing the desensitization 
protocol is a safe and time saving method. We had 11 
asthmatic patients in our trial (68%), but the rate of 
anaphylaxis was similar to other studies and only one 
of them could not accomplish the protocol. During the 
study we observed 21 episodes of anaphylaxis among 
498 administered doses, the mean number of episodes 
were 1.17 (median=0.5). The likelihood of accidental 
exposure in preschool-aged children has been 
determined as 71% in 3-year period and approximately 
11% of them graded as severe anaphylaxis.
26
 However, 
in milk OITs like ours, rate of anaphylaxis is less than 
natural exposures.
3,11,12,16,26 
Of note, we did not find any 
significant correlation between risk factors such as 
aeroallergen and the number of anaphylaxis, in contrast 
to a review by Elizur et al. that reported asthma as a 
risk factor for severe anaphylaxis and a threat to OIT 
efficacy.
14
 During the trial one other patient failed to 
finish the protocol due to abdominal pain, after 
evaluation she was diagnosed as EoE. Maggadottir et al. 
showed development of EoE in children after OIT 
treatment,
9
 which was found in our patient as well. Our 
current understanding from EoE pathogenesis suggest 
that disease occurrence is not related to IgE-mediated 
food allergy, although both may arise concurrently in 
the same individual. Some studies have proposed that 
some premedications like cromoglycate acid or 
cetirizine are necessary to decrease allergy symptoms 
during OIT treatment decrease allergy.
5,6
 Omalizumab 
has been successfully experienced in cases with 
refractory anaphylaxis in tolerance induction 
protocols.
27
 Although a large number of evidence show 
the successful results of OIT, there are some  concerns 
about the future of OIT. It is worth noting that to date, 
our patients have tolerated cow’s milk, 1 year after the 
desensitization procedure. However, further follow up 
and challenge would be valuable.  
We indicated that serum sIgE to milk, casein, α-
lactalbumine, and β- lactoglobuline, had significantly 
decreased after desensitization. However, Zapatero et al 
just could show reduced IgE against casein in response 
to desensitization treatment.
24
 In our study, we could 
not predict outcome of OIT treatment in our patients 
based on their SPT and specific IgE results. It needs 
more investigation, as currently we are recruiting more 
patients to the similar study 
In this study, we successfully used personalized 
dose desensitization protocol for patients with cow’s 
milk anaphylaxis. It should be noted that although 
concerns regarding the safety of OIT and its long term 
efficacy remains, food desensitization treatment has 
opened a new window to the future of food allergy 
treatment. We propose that personalizing the milk 
desensitization protocol is an effective and reasonably 
safe method; moreover, it save time and improve 
patients’ cooperation. Further studies should be done to 
determine the optimum time of intervention for 
treatment of patients suffering from food allergies. 
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